Shots: The approval is based on P-III EORTC1325/KEYNOTE-054 trial results assessing Keytruda (pembrolizumab,200mg, q3w) vs PBO in 1019 patients in the ratio (1:1) with completely resected stage IIIA, IIIB or […]readmore
Tags : Involvement